跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CAR-T-19
首页
药物
CAR-T-19
CAR-T-19
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
CAR-EXPRESSING T CELLS AND CAR EXPRESSION VECTOR
US 2021309712 A1
申请人: NOILE IMMUNE BIOTECH INC
优先权: 2018
CN
EP
US
WO
5 件公开
ANTI-CD22 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC CONSTRUCTS
EP 4188952 A4
申请人: NAT RES COUNCIL CANADA
优先权: 2020
CN
EP
US
WO
5 件公开
TREATMENT OF CANCER USING HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
EP 2970482 B1
申请人: NOVARTIS AG
优先权: 2013
CN
EP
4 件公开
PHARMACEUTICAL COMPOSITION FOR PREVENTING CYTOKINE STORM
EP 4292593 A4
申请人: UNIV KINKI
优先权: 2021
EP
US
WO
3 件公开
HUMANIZED ANTIGEN-BINDING DOMAINS AGAINST CD19 AND METHODS OF USE
EP 4286415 A2
申请人: KITE PHARMA INC
优先权: 2017
EP
WO
2 件公开
Malignant glioma CAR-T therapeutic vector based on OCTS technology, and construction method and application thereof
US 10934357 B2
申请人: SHANGHAI UNICAR THERAPY BIO MEDICINE TECH CO LTD
优先权: 2017
CN
US
2 件公开
OCTS technology-based pancreatic cancer and malignant mesothelioma CAR-T therapeutic vector, construction method therefor, and use thereof
US 11098123 B2
申请人: SHANGHAI UNICAR THERAPY BIO MEDICINE TECH CO LTD
优先权: 2017
CN
US
2 件公开
T CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR
US 2020207852 A1
申请人: MASSACHUSETTS GEN HOSPITAL
优先权: 2017
US
WO
2 件公开
MONOCLONAL ANTIBODY WHICH FIGHTS CD19 AND APPLICATION THEREOF
EP 3901174 A4
申请人: BIOSWAN LABORATORIES INC
优先权: 2018
EP
US
2 件公开
FULLY HUMAN ANTIBODY TARGETING CD19 AND APPLICATION THEREOF
EP 3974452 A4
申请人: NANJING IASO BIOTHERAPEUTICS CO LTD
优先权: 2019
CN
EP
2 件公开
第 1 / 6 页
上一页
下一页
药物
反馈